
From: Omar Jabri <ojabri@apotex.com>
Sent: Friday, May 15, 2026 5:50 AM
To: Jesse Schumaker
Subject: RE: Vykate XR Orange Book Patent - Petition for Post Grant Review



Jesse:

It's been some time since we last communicated. No one is questioning your or the Company's resolve to defend its patent. But, now that the PGR has been filed – a Petition that we believe is well reasoned – perhaps it makes sense to have that conversation I alluded to previously.

At bottom, we remain of the opinion that a productive discussion to see if there might be a business solution to the current circumstances makes sense. Let me know if you disagree, but otherwise, I look forward to scheduling something. Thanks.

Omar

From: Jesse Schumaker <jschumaker@solenolife>
Sent: Friday, February 13, 2026 4:14 PM
To: Omar Jabri <ojabri@apotex.com>
Subject: RE: Vykate XR Orange Book Patent - Petition for Post Grant Review

Caution: This is an external email. Be mindful when clicking links or opening attachments. If unsure, please report it using the Phish Alert Button (PAB).

Solenolife Confidential

Omar,

We are prepared to defend our patents and are not interested in a pre-filing discussion.

Jesse Schumaker | General Counsel
Solenolife Therapeutics, Inc. | 100 Marine Parkway, Suite 400 | Redwood City, CA 94065
jschumaker@solenolife | 917-312-6817



From: Omar Jabri <ojabri@apotex.com>
Sent: Friday, February 13, 2026 12:54 PM

Solenolife Therapeutics, Inc.
Exhibit 2032
Apotex v. Solenolife
PGR2026-00034
Ex. 2032-001

To: Jesse Schumaker <jschumaker@solenolife.com>

Subject: RE: Vykat XR Orange Book Patent - Petition for Post Grant Review

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hello, Mr. Schumaker –

I am following up on my email from earlier this week concerning Apotex's intention to file a post-grant review in respect of the '895 patent. Should Soleno wish to have pre-filing discussions in an attempt to seek a business-to-business resolution, please let me know.

Best regards,
Omar

From: Omar Jabri

Sent: Tuesday, February 10, 2026 1:46 PM

To: 'jschumaker@solenolife.com' <jschumaker@solenolife.com>

Subject: Vykat XR Orange Book Patent - Petition for Post Grant Review

Mr. Schumaker:

I serve as Head of IP Strategy for Apotex Inc., a generic pharmaceutical company headquartered in Toronto. Apotex's core mission is to improve everyday access to affordable, innovative medicines and health products for patients and consumers worldwide.

I am reaching out in your capacity as General Counsel of Soleno Therapeutics, Inc. to explore an opportunity for pre-dispute discussions regarding U.S. Patent No. 12,419,895 (the "'895 patent"), which is listed in the FDA's Orange Book for Vykat XR® (diazoxide choline tablets). Our aim is to explore a mutually advantageous business resolution.

We believe a direct, business-to-business dialogue is the most efficient way to avoid the substantial cost and risk associated with post-grant review of the '895 patent. To that end, Apotex would welcome a brief introductory call to share additional context and explore options. By way of example, and without limitation, Apotex would be open to discussing the terms of a license under the '895 patent to further our goal of bringing affordable generic options to patients. To the extent it would be helpful to Soleno to evaluate this opportunity, Apotex is willing to share a copy of the PGR petition under suitable confidentiality protections.

If convenient, please let me know a few windows in the coming days for a short call, or I can propose times that work on my end.

Thank you for your consideration. I look forward to your response.

Best regards,
Omar

Omar Jabri

Head of IP Strategy
Apotex Inc.
Cell: 416-574-7616 | www.apotex.com 



This email and any attachments thereto may contain private, confidential, and privileged material for the sole use of the intended recipient. Any review, copying, or distribution of this email (or any attachments thereto) by others is strictly prohibited. If you are not the intended recipient, please contact the sender immediately and permanently delete the original and any copies of this email and any attachments thereto.

This email and any attachments thereto may contain private, confidential, and privileged material for the sole use of the intended recipient. Any review, copying, or distribution of this email (or any attachments thereto) by others is strictly prohibited. If you are not the intended recipient, please contact the sender immediately and permanently delete the original and any copies of this email and any attachments thereto.